Vericel stock hits 52-week low at 30.23 USD

Vericel Corp’s stock reached a 52-week low of 30.23 USD, highlighting a challenging year for the company. According to InvestingPro data, the company maintains strong fundamentals with a current ratio of 4.97, indicating robust liquidity. Over the past year, the stock has experienced a significant decline, with a 1-year change of -33.79%. Despite these challenges, the company has achieved 16.13% revenue growth in the last twelve months. InvestingPro analysis suggests the stock is currently undervalued, with analyst targets indicating potential upside. Investors are closely monitoring Vericel’s performance as the company navigates these hurdles in a volatile market environment. For deeper insights into Vericel’s valuation and growth prospects, check out the comprehensive Pro Research Report, available exclusively on InvestingPro.

In other recent news, Vericel Corporation reported its second-quarter 2025 earnings, showing a narrowed net loss and increased revenue. The company’s earnings per share (EPS) was a loss of $0.01, which was better than the forecasted loss of $0.03. However, revenue slightly missed expectations, coming in at $63.24 million compared to the anticipated $64.61 million. Canaccord Genuity maintained its Buy rating on Vericel but lowered the stock price target to $58 from $61, citing a mixed performance in the latest quarterly results. The MACI product fell short of revenue targets, while Epicel’s revenue was also lower than expected despite a high number of biopsies. BTIG downgraded Vericel’s stock from Buy to Neutral, removing its previous $45 price target, due to limited growth prospects for the MACI Arthro product. In contrast, TD Cowen reiterated a Buy rating with a $55 price target, expressing confidence in the MACI Arthro’s potential to sustain significant growth. MACI Arthro recently received regulatory approval and is expanding across the United States. These developments reflect varied analyst perspectives on Vericel’s future growth potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.